MetSense Pilot and Feasibility
Enrolling by invitation · Not applicable
Conditions studied: Serious Mental Illness, Type 2 Diabetes
In brief
People with serious mental illness have high risk for type 2 diabetes due to multiple risk factors, including the metabolic side effects of psychotropic medications that are used to treat these conditions. Type 2 diabetes is preventable through lifestyle and pharmacological interventions, but many people with serious mental illness do not receive regular screening for type 2 diabetes risk. In many health care settings, clinical pharmacists are increasingly managing patients with serious mental illness and have expertise in monitoring the metabolic side effects of psychotropic medications. This study evaluates the feasibility and acceptability of using a diabetes prediction model that is based on electronic health record data (the MetSense risk flag) to alert clinical pharmacists about patients who are at high diabetes risk, prompting these clinicians to prioritize diabetes risk management services.
Key facts
- Study ID
- NCT07264062
- Run by
- Kaiser Permanente
- People needed
- 20000
- Starts
- 2025-12-01
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2026-02-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18 or older
- Diagnosed with schizophrenia, another psychotic disorder, or bipolar disorder
- Included in a clinical pharmacist population management program for serious mental illness within Kaiser Permanente Northern California
Where it is running
- KPNC Division of Research — Pleasanton, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.